State-of-the-art MRI technology bypasses need for biopsy
Featured on the cover of the Journal of Urology, Drs. Pedrosa, Cadeddu, and colleagues report a new multiparametric MRI approach with high sensitivity and specificity for the detection of clear cell renal cell carcinoma, which may reduce the need for biopsies. Press Release • Video
HIF-2 inhibitor effective against kidney cancer
The results of a Phase I clinical trial using a first-in-class HIF-2alpha inhibitor called PT2385 are reported in the Journal of Clinical Oncology. The drug, developed by Peloton Therapeutics, showed activity in highly pretreated patients and minimal side-effects. KCP researcher, Dr. Kevin Courtney, was the UTSW site PI and corresponding author of the report. Press Release
KCP hosts first retreat for trainees
The KCP hosted a retreat for trainees (medical students, interns, residents, fellows...) to discuss trainee projects, research opportunities, resources, and funding opportunities. Two $1,000 awards for best research projects were given - one to a student, Daniel Li (MS2), and one to a physician, Ali Pirasteh, M.D. (Assistant Instructor).
Improved survival rates across stages
Updated Outcomes analysis shows higher survival rates at UTSW Kidney Cancer Program compared to National Benchmarks, with survival rates double national benchmarks for stage IV kidney cancer patients, and improved across stages.
KCP Golf Tournament
The “Tee Off Fore Kidney Cancer” golf tournament fundraiser, held at the Cowboys Golf Club and organized by KCP Patient Advocate Merlinda Chelette and the Kidney Cancer Coalition raises over $27,000. Video
$10 million allocation from CDMRP supports 4 kidney cancer-specific awards
The Congressionally-directed Kidney Cancer Research Program releases 4 grant funding opportunities. The opportunities focus on innovation and are geared towards team science and the development of the first ever Clinical Trials Kidney Cancer Consortium. "These opportunities have the potential to transform kidney cancer research," said Dr. Brugarolas, who chairs the Programmatic and Vision Setting Panel.
Dr. Hammers leads BMS-sponsored CheckMate-214 phase-3 trial
Results from the BMS-sponsored CheckMate-214 phase-3 trial, for which Dr. Hammers is a co-PI, are presented at the European Society for Medical Oncology annual meeting, and show improved overall survival with ipilimumab/nivolumab compared to sunitinib heralding a new standard of care for patients with metastatic kidney cancer. Press Release • Interview
UTSW Urology expertise to benefit JPS Hospital
The Urology Department, the surgical backbone of the Kidney Cancer Program begins providing care at John Peter Smith Hospital (also known as JPS Hospital), a 573-bed county hospital in Fort Worth, ensuring that Tarrant County residents get state-of-the-art urologic care, including robotic partial nephrectomy, laparoscopic and robotic radical nephrectomy, and advanced cancer care in a multi-disciplinary format. Tarrant county residents will benefit from the Kidney Cancer Program thought leaders in urology, medical oncology, radiation oncology, pathology, and radiology, who will review complex cases in a virtual multi-disciplinary format to ensure that the highest caliber care is delivered. We are very excited and proud to offer our services to this unique group of patients.
Private Facebook support page launched for patients
The KCP launches a private patient support Facebook page, a dedicated forum for kidney cancer patients and their family and friends to discuss issues, questions, and concerns, and to help support each other on their journeys.